Skip to Main Content

Paper Details

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Clin Cancer Res
7
2023
AML, BET protein family, CTCL, MDS, Molibresib, NHL, acute myeloid leukemia, anemia, cutaneous T cell lymphoma, febrile neutropenia, gastrointestinal and thrombocytopenia, hematologic malignancies, hematological malignancies, molibresib, multiple myeloma, myelodysplastic syndrome, non-Hodgkin's lymphoma, patients, thrombocytopenia, tumor
Author NameAffiliation
Gautam BorthakurThe University of Texas MD Anderson Cancer Center
Brian J P HuntlyUniversity of Cambridge
Brian J P HuntlyUniversity of Cambridge
Daniel A PollyeaUniversity of Colorado School of Medicine
Anastasia WyceCollegeville
  • 1 - 5

Datasets

Release 1.2